



UNIVERSITY OF LEEDS

This is a repository copy of *Embarking on a Chemical Space Odyssey*.

White Rose Research Online URL for this paper:

<http://eprints.whiterose.ac.uk/114076/>

Version: Accepted Version

---

**Article:**

Chow, SY [orcid.org/0000-0002-3600-0497](https://orcid.org/0000-0002-3600-0497) and Nelson, AS  
[orcid.org/0000-0003-3886-363X](https://orcid.org/0000-0003-3886-363X) (2017) *Embarking on a Chemical Space Odyssey*. *Journal of Medicinal Chemistry*, 60 (9). pp. 3591-3593. ISSN 0022-2623

<https://doi.org/10.1021/acs.jmedchem.7b00423>

---

© 2017 American Chemical Society. This document is the Accepted Manuscript version of a Published Work that appeared in final form in *Journal of Medicinal Chemistry*, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see <https://doi.org/10.1021/acs.jmedchem.7b00423>. Uploaded in accordance with the publisher's self-archiving policy.

**Reuse**

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

# Embarking on a Chemical Space Odyssey

Shiao Y. Chow and Adam Nelson\*

School of Chemistry and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS2 9JT, UK

Corresponding author's email address: a.s.nelson@leeds.ac.uk

## **Abstract:**

The chemical space explored in drug discovery programmes is restricted by a narrow reaction toolkit, and the frequent failure of even these reactions with polar and functionalised substrates. Recently, high-throughput reaction optimisation has been integrated into discovery workflows, thereby increasing the value of specific reaction classes in the toolkit. It is likely that high-throughput experimentation will enable expansion of the synthetic chemistry that is widely exploited in discovery, thereby increasing innovation in medicinal chemistry.

## **Text:**

The discovery of bioactive small molecules is an enduring challenge in both medicinal chemistry and chemical biology. Discovery workflows generally involve design–make–test cycles that necessarily rely on the synthetic accessibility of the molecules to be tested. Researchers thus tend to gravitate towards a narrow toolkit<sup>1</sup> of highly reliable transformations which has tended to increase attention on flatter and more lipophilic compounds.<sup>2</sup> Even with this narrow toolkit, reactions involving polar and highly functionalised substrates are systematically more likely to fail, resulting in “logP drift” in which the arrays of produced compounds that are less polar than those designed.<sup>3</sup> In this issue of *Journal of Medicinal Chemistry*, Cernak and co-workers from Merck describe the application of high-throughput reaction optimisation to expand the diversity of the chemical space that was explored in a drug discovery programme.<sup>4</sup>


Recently, high-throughput experimentation has been adopted by a number of pharmaceutical companies to identify efficient synthetic methods to underpin medicinal chemistry programmes. In 2015, the team from Merck also described the high-throughput, nanomole-scale optimisation of palladium-catalysed cross-coupling reactions.<sup>5</sup> Crucially, the approach enabled the identification optimal conditions for a wide range of couplings

between pairs of highly-functionalised substrates. In the current study,<sup>4</sup> high-throughput experimentation was used to identify reliable reaction conditions for S<sub>N</sub>Ar chemistry required to underpin the discovery of diacylglycerol acyltransferase 1 (DGAT1) inhibitors.

The starting point for the investigation was a specific benzimidazole lead compound (IC<sub>50</sub>: 52 nM) (Panel A, Figure). Initial efforts to prepare an array of eight analogues met with limited success: in only four of the attempted S<sub>N</sub>Ar reactions between the 2-chloro pyridine **E1** and an amine nucleophile was a low (5%-32%) yield of the required product isolated (Panel B, top). As a result, the development of structure-activity relationships (SAR) was significantly hampered.

Next, the synthesis of a further 28 analogues was attempted (Panel B, bottom). In each case, a pair of substrates was reacted under specific reaction conditions (either DIPEA as base in DMA; or K<sub>2</sub>CO<sub>3</sub> as base in DMSO). With the 2-chloro pyridine **E1** as electrophile, only 9 of the 19 designed products were obtained, of which only 4 were isolated in >10% yield. The 2-fluoro pyridine **E2** fared better, and all 9 of the designed products were obtained; nonetheless, two of the products were obtained in <10% yield, and the use of DMA at high temperature led to the formation of a 2-dimethylamino pyridine by-product in many cases.

A more systematic approach to reaction optimisation enabled the synthesis of analogues needed to define meaningful SAR. All 24 combinations of six bases and four solvents were screened in the optimisation of the S<sub>N</sub>Ar reaction between the 2-fluoro pyridine **E2** and the piperidine **N2** (Panel C, top). DIPEA and NaHCO<sub>3</sub> were identified as the best-performing bases, having resulted in consistently good conversion with all four solvents. Furthermore, the solvents CPME and NMP were prioritised based on the observed yields and their chemical inertness and solvation ability.



**Figure:** High-throughput optimisation of S<sub>N</sub>Ar chemistry, and exploitation of the optimised conditions in analogue synthesis. Panel A: Synthesis of the lead molecule. Panel B: Attempted initial development of SAR using specific synthetic methods. Panel C: Identification of reaction conditions suitable for the synthesis of a wide range of analogues. Panel D: Application of the optimised reaction conditions in the synthesis of a wide range of analogues needed to define SAR.

To identify the robust reaction conditions for the synthesis of a wide range of analogues, the four prioritised base/solvent combinations (DIPEA or NaHCO<sub>3</sub> with CPME or NMP) were evaluated with a wider range of substrate combinations (Panel C, bottom). The electrophile **E2** was reacted with six different nucleophiles, and the nucleophile **N1** was reacted with six different electrophiles. With DIPEA or NaHCO<sub>3</sub> in NMP, 10 of the 12 substrate combinations

gave an acceptable yield of the required product. Remarkably, neither of these conditions had been optimal in the previous screen of the reaction between **E2** and **N2** (Panel C, top), demonstrating the value of investigating alternative reaction conditions with a range of different substrate combinations.

As a result of the high-throughput reaction optimisation, NaHCO<sub>3</sub> in NMP was taken forward, partly because the partial solubility of the base in organic solvents simplified product purification. The optimised conditions enabled the successful synthesis of 35 (of 43) analogues with activities spanning over three orders of magnitude (Panel D). The most potent compound (IC<sub>50</sub>: 6 nM; MW: 472) was considered an attractive starting point for lead optimisation. Furthermore, the optimised reaction conditions were also exploited in these subsequent lead optimisation activities.

High-throughput reaction optimisation to enable the functional molecule discovery is nonetheless still in its infancy. Published examples of the approach are restricted to the optimisation of reactions that are already in the medicinal chemists' narrow toolkit:<sup>1</sup> for example, Pd-catalysed cross couplings<sup>5</sup> and, now, S<sub>N</sub>Ar chemistry.<sup>4</sup> The approach has thereby allowed reactions within the established toolkit to be exploited more effectively, and has expanded the range of specific analogues that can be prepared.

Considerable advances are, however, still required in order to increase dramatically the range of innovative high-quality small molecules that may be discovered. For this to happen, the toolkit of reactions actually exploited in discovery workflows needs to be expanded markedly. Remarkably, no new reactions have been added to this toolkit over the last 30 years, despite an unprecedented era of invention in synthetic chemistry. As a result, researchers from AstraZeneca have provocatively asked<sup>1a</sup> where all of the new reactions have gone!

High-throughput experimentation is already helping to address the greater challenge of expanding the reaction toolkit for small molecule discovery. First, screening can identify reactions with high robustness:<sup>6</sup> reactions that are compatible with a wide range of polar and functionalised substrates. Indeed, screening has identified several reactions with high robustness, for example arylations of sp<sup>3</sup>-hybridised carbon. Second, an emerging function-driven approach<sup>7</sup> – activity-directed synthesis – deliberately exploits inherently promiscuous reactions. Crucially, activity-directed synthesis can facilitate the discovery of functional small molecules with unexpected structures in parallel with associated synthetic routes.

## References

1. (a) Brown, D. G.; Boström, J. Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone? *J. Med. Chem.* **2016**, *59*, 4443-4458. (b) Roughley, S. D.; Jordan, A. M. The Medicinal Chemist's Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates. *J. Med. Chem.* **2011**, *54*, 3451-3479 (c) Barker, A.; Kettle, J. G.; Nowak, T.; Pease, J. E. Expanding medicinal chemistry space. *Drug Discovery Today* **2013**, *18*, 298-304.
2. Walters, W. P.; Green, J., Weiss, J. R.; Murcko, M. A. What Do Medicinal Chemists Actually Make? A 50-Year Retrospective. *J. Med. Chem.* **2011**, *54*, 6405-6416.
3. Nadin, A.; Hattotuwigama, C.; Churcher, I. Lead-Oriented Synthesis: A New Opportunity for Synthetic Chemistry. *Angew. Chem. Int. Ed.* **2012**, *51*, 1114-1122.
4. Cernak, T. et al. Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitors. *J. Med. Chem.*
5. Dreher et al. Nanomole-scale high-throughput chemistry for the synthesis of complex molecules. *Science* **2015**, *347*, 49-53.
6. (a) Schmink, J. R.; Bellomo, A.; Berritt, S. Scientist-Led High-Throughput Experimentation (HTE) and Its Utility in Academia and Industry. *Aldrichimica Acta*, **2013**, *46*, 71-80. (b) Collins, K. D.; Glorius, F. A robustness screen for the rapid assessment of chemical reactions. *Nature Chemistry* **2013**, *5*, 597-601.
7. (a) Karageorgis, G.; Warriner, S.; Nelson, A. Efficient discovery of bioactive scaffolds by activity-directed synthesis, *Nature Chemistry* **2014**, *6*, 872-876; (b) Karageorgis, G.; Dow, M.; Aimon, A; Warriner, S.; Nelson, A. Activity-Directed Synthesis with Intermolecular Reactions: Development of a Fragment into a Range of Androgen Receptor Agonists, *Angew. Chem. Int. Ed.* **2015**, *54*, 13583-13544.

**Acknowledgements:** We thank EPSRC (EP/N025652/1) for funding.

**Table of Content Graphic**

